| Identification | Back Directory | [Name]
Z-PHE-PHE-FLUOROMETHYLKETONE | [CAS]
108005-94-3 | [Synonyms]
Z-FF-FMK
Z-PHE-PHE-FMK
Cathepsin L-IN-2
Z-PHE-PHE-FLUOROMETHYLKETONE
Carbamic acid, [2-[[3-fluoro-2-oxo-1-(phenylmethyl)propyl]amino]-2-oxo-1-(phenylmethyl)ethyl]-, phenylmethyl ester (9CI) | [Molecular Formula]
C27H27FN2O4 | [MDL Number]
MFCD03453604 | [MOL File]
108005-94-3.mol | [Molecular Weight]
462.51 |
| Chemical Properties | Back Directory | [Boiling point ]
707.5±60.0 °C(Predicted) | [density ]
1.214±0.06 g/cm3(Predicted) | [storage temp. ]
−20°C | [solubility ]
DMSO: 20mM | [form ]
solid | [pka]
11.07±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Cathepsin L-IN-2 ((Rac)-Z-Phe-Phe-FMK) is an isomer of the Cathepsin L/B inhibitor Z-Phe-Phe-FMK (HY-141867), with an IC50 of 15 μM for cathepsin L. Z-Phe-Phe-FMK irreversibly blocks the proteolytic function of cathepsins by covalently binding to the cysteine residues in the active center of the enzyme. Cathepsin L-IN-2 and Z-Phe-Phe-FMK can be used to study neurodegenerative diseases (such as GRN-related frontotemporal dementia) and cancer invasion and metastasis. | [Biological Activity]
Cell permeable: yes''Primary Target
cathepsin L''Product does not compete with ATP.''Reversible: no | [IC 50]
Cathepsin B; cathepsin L | [References]
[1] Jonathan Frew, et al. Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency. Mol Neurodegener. 2020 Mar 16;15(1):21. DOI:10.1186/s13024-020-00369-5 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|